Fate Therapeutics Inc. (FATE) Trading Down 2.9%
Fate Therapeutics Inc. (NASDAQ:FATE)’s share price dropped 2.9% on Tuesday . The company traded as low as $2.58 and last traded at $2.65, with a volume of 106,626 shares. The stock had previously closed at $2.73.
FATE has been the topic of a number of research analyst reports. BMO Capital Markets reissued a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, May 10th. Wells Fargo & Co. restated a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Monday, July 11th. HC Wainwright restated a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, August 9th. Finally, Leerink Swann restated an “outperform” rating and issued a $4.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, June 21st. Eight research analysts have rated the stock with a buy rating, Fate Therapeutics has an average rating of “Buy” and a consensus target price of $6.29.
The firm’s 50 day moving average is $1.94 and its 200 day moving average is $1.84. The company’s market cap is $77.15 million.
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. On average, equities analysts predict that Fate Therapeutics Inc. will post ($1.12) EPS for the current year.
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.